Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02162329 · ClinicalTrials.gov registry record · NA

Effects of Meditation on Cognitive Function and Quality of Life

A NA study of Breast Cancer, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
NA
Development phase
35
Enrollment target
2
Study locations

NCT02162329: Completed NA study of Breast Cancer, sponsored by M.D. Anderson Cancer Center.

NCT02162329 is a NA study of Breast Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 35 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02162329, a NA study of Breast Cancer, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
2
Study locations

Study Summary

The goal of this research study is to test Tibetan meditation as a therapy to teach cancer patients to change their brain functioning and to improve quality of life. Researchers want to compare the cancer patients' outcomes to people who have never had cancer.

Primary Outcome

Primary analyses based on difference scores of continuous variables measured at baseline and 8 weeks later. T tests or Wilcoxon two-sample tests used, depending on the distribution of the data. Reliable change index (RCI) used for the cognitive tasks. RCI based on standard error of measurement for each assessment and takes into account baseline levels of performance for any participant. A chi-square test used to compare the proportions of participants that fall into each classification in the me

Conditions Studied

Interventions

  • BEHAVIORAL Questionnaires
  • PROCEDURE Electroencephalography (EEG)
  • PROCEDURE Magnetic Resonance Imaging (fMRI
  • BEHAVIORAL Meditation Classes

Study Locations (2)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Other

  • Hospital Israelita Albert Einstein (HIAE) - São Paulo

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2013-10-22
Est. Completion 2022-10-18
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What the finished NCT02162329 record still lists

NCT02162329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Questionnaires is the first listed.

NCT02162329 reports a single indexed study location in Texas, Other.

Frequently Asked Questions

What is clinical trial NCT02162329 about?

NCT02162329 is a clinical study titled "Effects of Meditation on Cognitive Function and Quality of Life". The goal of this research study is to test Tibetan meditation as a therapy to teach cancer patients to change their brain functioning and to improve quality of life. Researchers want to compare the cancer patients' outcomes to people who have never had cancer.

What is the current status of trial NCT02162329?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2013-10-22. Estimated completion is 2022-10-18.

What conditions does trial NCT02162329 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT02162329?

The interventions under investigation include: Questionnaires (BEHAVIORAL), Electroencephalography (EEG) (PROCEDURE), Magnetic Resonance Imaging (fMRI (PROCEDURE), Meditation Classes (BEHAVIORAL).

Who is sponsoring clinical trial NCT02162329?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02162329 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02162329's enrollment target sits among peer trials

35 922nd of 1224 higher than 298 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01697371 · 35 participants · NA

    Proton Therapy in the Treatment of Liver Metastases

  • NCT01940757 · 35 participants · Phase 1

    Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

  • NCT02235857 · 35 participants · NA

    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

  • NCT02637934 · 35 participants · Phase 1

    Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02162329, the US trial registry maintained by the National Library of Medicine. NCT02162329 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.